STAT5A and acute myeloid leukemia: Conversely, low RhoH expression results in increased STAT5A activation and increased transcription of a known STAT5A target, IRF1. Phenotypically, IRF1 expression results in the increased surface expression of CD123, which is a cell surface marker with elevated expression on acute myeloid leukaemia (AML) cells.